There are two major sticking points at issue. The first is a provision preventing the government from leveraging its prescription drug buying power to bargain for lower prices. The second is the roughly $125 billion that will go to large HMO's and insurance providers.
On Point examines this prescription for Medicare.
David Hawkings, Senior Editor for Congressional Quarterly Magazine
Stuart Altman, Professor of Health care policy at the Heller school for Social Policy and Management at Brandeis University
Nina Owcharenko, Senior Policy Analyst for the Heritage Foundation
Jack Beatty, On Point News Analyst and Senior Editor at the Atlantic Monthly.
This program aired on November 24, 2003.